Armata Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.906
- Today's High:
- $3.4
- Open Price:
- $2.97
- 52W Low:
- $0.83
- 52W High:
- $5.79
- Prev. Close:
- $3.04
- Volume:
- 29829
Company Statistics
- Market Cap.:
- $96.14 million
- Book Value:
- 1.261
- Revenue TTM:
- $5.45 million
- Operating Margin TTM:
- -599.82%
- Gross Profit TTM:
- $-15541000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.12%
- Return on Equity TTM:
- -94.18%
Company Profile
Armata Pharmaceuticals Inc had its IPO on 2011-03-09 under the ticker symbol ARMP.
The company operates in the Healthcare sector and Biotechnology industry. Armata Pharmaceuticals Inc has a staff strength of 69 employees.
Stock update
Shares of Armata Pharmaceuticals Inc opened at $2.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.91 - $3.4, and closed at $2.98.
This is a -1.97% slip from the previous day's closing price.
A total volume of 29,829 shares were traded at the close of the day’s session.
In the last one week, shares of Armata Pharmaceuticals Inc have slipped by -7.17%.
Armata Pharmaceuticals Inc's Key Ratios
Armata Pharmaceuticals Inc has a market cap of $96.14 million, indicating a price to book ratio of 1.5068 and a price to sales ratio of 11.15.
In the last 12-months Armata Pharmaceuticals Inc’s revenue was $5.45 million with a gross profit of $-15541000 and an EBITDA of $-31742000. The EBITDA ratio measures Armata Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Armata Pharmaceuticals Inc’s operating margin was -599.82% while its return on assets stood at -30.12% with a return of equity of -94.18%.
In Q3, Armata Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7%.
Armata Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Armata Pharmaceuticals Inc’s profitability.
Armata Pharmaceuticals Inc stock is trading at a EV to sales ratio of 148.1376 and a EV to EBITDA ratio of -2.6079. Its price to sales ratio in the trailing 12-months stood at 11.15.
Armata Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $92.88 million
- Total Liabilities
- $7.00 million
- Operating Cash Flow
- $-1294000.00
- Capital Expenditure
- $1.53 million
- Dividend Payout Ratio
- 0%
Armata Pharmaceuticals Inc ended 2025 with $92.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $92.88 million while shareholder equity stood at $45.58 million.
Armata Pharmaceuticals Inc ended 2025 with $10.26 million in deferred long-term liabilities, $7.00 million in other current liabilities, 361000.00 in common stock, $-229460000.00 in retained earnings and $3.49 million in goodwill. Its cash balance stood at $25.38 million and cash and short-term investments were $25.38 million. The company’s total short-term debt was $2,223,000 while long-term debt stood at $0.
Armata Pharmaceuticals Inc’s total current assets stands at $33.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.87 million compared to accounts payable of $7.86 million and inventory worth $0.
In 2025, Armata Pharmaceuticals Inc's operating cash flow was $-1294000.00 while its capital expenditure stood at $1.53 million.
Comparatively, Armata Pharmaceuticals Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $2.98
- 52-Week High
- $5.79
- 52-Week Low
- $0.83
- Analyst Target Price
- $8
Armata Pharmaceuticals Inc stock is currently trading at $2.98 per share. It touched a 52-week high of $5.79 and a 52-week low of $5.79. Analysts tracking the stock have a 12-month average target price of $8.
Its 50-day moving average was $2.66 and 200-day moving average was $2.06 The short ratio stood at 1.43 indicating a short percent outstanding of 0%.
Around 7306.6% of the company’s stock are held by insiders while 376.3% are held by institutions.
Frequently Asked Questions About Armata Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.